STAT

It’s not just Democrats: In dueling drug pricing hearings, at least some Republicans slam pharma, too

It’s not just Democrats. In Tuesday's dueling drug pricing hearings, at least some Republicans slammed pharma, too.
Rep. Jim Jordan (R-Ohio)

WASHINGTON — Democrats here have, of late, been making far more noise about high prescription drug prices.

But at two dueling hearings on Tuesday, the most powerful Republicans on each committee made their own mark.

Rep. Jim Jordan of Ohio, the ranking member of the House Oversight Committee and a former chairman of the ultra-conservative Freedom Caucus, kicked off his panel’s hearing by offering his support for a controversial proposal that would inflame drug makers: to potentially cut the lucrative exclusivity periods the government grants drug makers for their products.

And Iowa Sen. Chuck Grassley, the chairman of the Senate Finance Committee, used part of his own speaking time

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks